Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
70.40
+0.21 (0.30%)
At close: Aug 20, 2025, 4:00 PM
71.63
+1.22 (1.74%)
After-hours: Aug 20, 2025, 4:54 PM EDT
Corcept Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Corcept Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $138.25, which forecasts a 96.38% increase in the stock price over the next year. The lowest target is $121 and the highest is $150.
Price Target: $138.25 (+96.38%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $142 → $137 | Strong Buy | Maintains | $142 → $137 | +94.60% | Aug 1, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $131 → $121 | Buy | Maintains | $131 → $121 | +71.87% | Aug 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $150 → $145 | Strong Buy | Maintains | $150 → $145 | +105.97% | May 6, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $128 → $131 | Buy | Maintains | $128 → $131 | +86.08% | Apr 3, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $130 → $142 | Strong Buy | Maintains | $130 → $142 | +101.70% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
917.03M
from 675.04M
Increased by 35.85%
Revenue Next Year
1.24B
from 917.03M
Increased by 35.22%
EPS This Year
1.41
from 1.23
Increased by 14.23%
EPS Next Year
2.71
from 1.41
Increased by 93.10%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 946.4M | 1.5B | 2.1B | ||
| Avg | 917.0M | 1.2B | 1.6B | ||
| Low | 876.3M | 1.0B | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.2% | 58.2% | 69.4% | ||
| Avg | 35.8% | 35.2% | 32.4% | ||
| Low | 29.8% | 10.2% | -10.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.60 | 4.16 | 7.70 | ||
| Avg | 1.41 | 2.71 | 6.11 | ||
| Low | 1.24 | 1.10 | 3.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 29.8% | 195.9% | 183.7% | ||
| Avg | 14.2% | 93.1% | 125.1% | ||
| Low | 1.2% | -21.9% | 34.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.